These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
27. A dose-escalation study of pemetrexed and docetaxel in non-small-cell lung cancer. Kotsakis A; Agelaki S; Vardakis N; Stathopoulos G; Vamvakas L; Kalykaki A; Kentepozidis N; Kontopodis E; Sfakiotaki G; Mavroudis D; Georgoulias V Cancer Chemother Pharmacol; 2011 Aug; 68(2):415-22. PubMed ID: 21069335 [TBL] [Abstract][Full Text] [Related]
28. Activity of second-line chemotherapy in docetaxel-refractory hormone-refractory prostate cancer patients : randomized phase 2 study of ixabepilone or mitoxantrone and prednisone. Rosenberg JE; Weinberg VK; Kelly WK; Michaelson D; Hussain MH; Wilding G; Gross M; Hutcheon D; Small EJ Cancer; 2007 Aug; 110(3):556-63. PubMed ID: 17577218 [TBL] [Abstract][Full Text] [Related]
29. Docetaxel in the treatment of metastatic castration-resistant prostate cancer (mCRPC): an observational study in a single institution. Schallier D; Decoster L; Braeckman J; Fontaine C; Degrève J Anticancer Res; 2012 Feb; 32(2):633-41. PubMed ID: 22287756 [TBL] [Abstract][Full Text] [Related]
30. Weekly docetaxel as second line treatment after mitozantrone for androgen-independent prostate cancer. Joshua AM; Nordman I; Venkataswaran R; Clarke S; Stockler MR; Boyer MJ Intern Med J; 2005 Aug; 35(8):468-72. PubMed ID: 16176469 [TBL] [Abstract][Full Text] [Related]
31. A phase 2 study of patupilone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel: Canadian Urologic Oncology Group study P07a. Chi KN; Beardsley E; Eigl BJ; Venner P; Hotte SJ; Winquist E; Ko YJ; Sridhar SS; Weber D; Saad F Ann Oncol; 2012 Jan; 23(1):53-58. PubMed ID: 21765178 [TBL] [Abstract][Full Text] [Related]
32. Paclitaxel in combination with carboplatin as salvage treatment in patients with castration-resistant prostate cancer: a Hellenic oncology research group multicenter phase II study. Kentepozidis N; Soultati A; Giassas S; Vardakis N; Kalykaki A; Kotsakis A; Papadimitraki E; Pantazopoulos N; Bozionellou V; Georgoulias V Cancer Chemother Pharmacol; 2012 Jul; 70(1):161-8. PubMed ID: 22660737 [TBL] [Abstract][Full Text] [Related]
33. The interval from the last cycle of docetaxel-based chemotherapy to progression is associated with the efficacy of subsequent docetaxel in patients with prostate cancer. Loriot Y; Massard C; Gross-Goupil M; Di Palma M; Escudier B; Bossi A; Chauchereau A; Fizazi K Eur J Cancer; 2010 Jul; 46(10):1770-2. PubMed ID: 20483588 [TBL] [Abstract][Full Text] [Related]
34. No additional benefit of adding ifosfamide to docetaxel in castration-resistant metastatic prostate cancer. Hervonen P; Tulijoki T; Kellokumpu-Lehtinen P Anticancer Res; 2012 Aug; 32(8):3305-9. PubMed ID: 22843906 [TBL] [Abstract][Full Text] [Related]
35. Long-term results of a prospective, Phase II study of long-term androgen ablation, pelvic radiotherapy, brachytherapy boost, and adjuvant docetaxel in patients with high-risk prostate cancer. Dibiase SJ; Hussain A; Kataria R; Amin P; Bassi S; Dawson N; Kwok Y Int J Radiat Oncol Biol Phys; 2011 Nov; 81(3):732-6. PubMed ID: 21036486 [TBL] [Abstract][Full Text] [Related]
36. Does failure of single hormone therapy delineate hormone refractoriness for prostate cancer? Kotwal S; Whelan P Scand J Urol Nephrol; 2008; 42(2):116-20. PubMed ID: 17907049 [TBL] [Abstract][Full Text] [Related]
37. A phase 2 study of carboplatin plus docetaxel in men with metastatic hormone-refractory prostate cancer who are refractory to docetaxel. Ross RW; Beer TM; Jacobus S; Bubley GJ; Taplin ME; Ryan CW; Huang J; Oh WK; Cancer; 2008 Feb; 112(3):521-6. PubMed ID: 18085595 [TBL] [Abstract][Full Text] [Related]
38. Salvage therapy with oral metronomic cyclophosphamide and methotrexate for castration-refractory metastatic adenocarcinoma of the prostate resistant to docetaxel. Gebbia V; Serretta V; Borsellino N; Valerio MR; Urology; 2011 Nov; 78(5):1125-30. PubMed ID: 22054386 [TBL] [Abstract][Full Text] [Related]
39. First- and second-line chemotherapy with docetaxel or mitoxantrone in patients with hormone-refractory prostate cancer: does sequence matter? Michels J; Montemurro T; Murray N; Kollmannsberger C; Nguyen Chi K Cancer; 2006 Mar; 106(5):1041-6. PubMed ID: 16456811 [TBL] [Abstract][Full Text] [Related]
40. Phase II study of pemetrexed in patients pretreated with an anthracycline, a taxane, and capecitabine for advanced breast cancer. O'Shaughnessy JA; Clark RS; Blum JL; Mennel RG; Snyder D; Ye Z; Liepa AM; Melemed AS; Yardley DA Clin Breast Cancer; 2005 Jun; 6(2):143-9. PubMed ID: 16001992 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]